Literature DB >> 1082250

Portal hypertension in infants and children with histiocytosis X.

J L Grosfeld, J F Fitzgerald, V M Wagner, W A Newton, R L Baehner.   

Abstract

Histiocytosis X describes a disease characterized by histiocytic infiltration of the reticuloendothelial system, skin, bones, and pituitary gland. The disseminated form frequently occurs in infants and children. Chemotherapy has significantly improved the prognosis in this disorder. Sixty-three per cent of survivors, however, have some residual disability related to fibrosis of tissues previously infiltrated by histiocytes. In instances of liver involvement, healing by fibrosis may result in cirrhosis with portal hypertension and bleeding esophageal varices. Clinical findings include hepatosplenomegaly, jaundice, ascites, hypoalbuminemia, prolonged prothrombin time, and Bromsulphalein retention. Histologic examination of the liver shows a characteristic dense "macronodular" periportal cirrhotic pattern. Three children with portal hypertension and bleeding varices due to healed histiocytosis X were sucessfully managed by portosystemic shunt procedures. Portacaval, mesocaval, and central splenorenal shunts were equally effective in relieving poral hypertension. These children had neither recurrence of bleeding nor evidence of encephalopathy. Two children remain well whereas in one patient a primary hepatoma developed fourteen years posthung and he died of pulmonary metastases. Portosystemic shunt procedures effectively relieve the threat of potentially fatal variceal hemorrhage and improve the opportunity for long-term survival in children with cirrhosis and portal hypertension due to healed histiocytosis X.

Entities:  

Mesh:

Year:  1976        PMID: 1082250     DOI: 10.1016/0002-9610(76)90431-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Liver transplantation in patients with Langerhans' cell histiocytosis.

Authors:  A C Stieber; C Sever; T E Starzl
Journal:  Transplantation       Date:  1990-08       Impact factor: 4.939

2.  Histiocytosis X and erythropoietic protoporphyria.

Authors:  R A Graham-Brown; P J Scheuer; I Sarkany
Journal:  J R Soc Med       Date:  1984-03       Impact factor: 5.344

3.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

4.  Sclerosing cholangitis and histiocytosis X.

Authors:  H H Thompson; H A Pitt; K J Lewin; W P Longmire
Journal:  Gut       Date:  1984-05       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.